These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6120379)

  • 1. Pyrazinamide is a major antituberculosis drug.
    Pretet S; Liard R; Perdrizet S
    Lancet; 1982 Feb; 1(8268):399. PubMed ID: 6120379
    [No Abstract]   [Full Text] [Related]  

  • 2. Pyrazinamide in tuberculosis.
    Ormerod LP; Horsfield N
    Lancet; 1981 Dec 19-26; 2(8260-61):1417. PubMed ID: 6118781
    [No Abstract]   [Full Text] [Related]  

  • 3. Rifampin and pyrazinamide for treatment of latent tuberculosis infection.
    Cook PP
    Clin Infect Dis; 2006 Mar; 42(6):892; author reply 892-3. PubMed ID: 16477576
    [No Abstract]   [Full Text] [Related]  

  • 4. Contribution of pyrazinamide to antituberculosis chemotherapy.
    Geiter LJ
    J Infect Dis; 1991 Sep; 164(3):610. PubMed ID: 1869849
    [No Abstract]   [Full Text] [Related]  

  • 5. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antituberculosis drugs and hepatotoxicity.
    Yew WW; Leung CC
    Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. US guidelines for treatment of latent tuberculosis revised.
    McCarthy M
    Lancet; 2001 Sep; 358(9284):816. PubMed ID: 11564495
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 10. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.
    McElroy PD; Ijaz K; Lambert LA; Jereb JA; Iademarco MF; Castro KG; Navin TR
    Clin Infect Dis; 2005 Oct; 41(8):1125-33. PubMed ID: 16163632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of pyrazinamide in tuberculosis chemotherapy.
    Steele MA; Des Prez RM
    Chest; 1988 Oct; 94(4):845-50. PubMed ID: 3048929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of pyrazinamide on the liver in patients with tuberculosis. An ultrastructural study].
    Pilheu JA; de Salvo MC; Arias RF; Koch OR
    Medicina (B Aires); 1985; 45(1):15-9. PubMed ID: 3880102
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
    Ijaz K; McElroy PD; Jereb J; Navin TR; Castro KG
    Clin Infect Dis; 2007 Feb; 44(3):464-5; author reply 465. PubMed ID: 17205462
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
    van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
    Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
    Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
    Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Liver function in tuberculosis treated with pyrazinamide, cycloserine, ethionamide and isoniazid].
    Uçak D; Uçak A
    Tip Fak Mecm; 1969; 32(1):48-52. PubMed ID: 5398987
    [No Abstract]   [Full Text] [Related]  

  • 18. [Histological follow-up studies on drug induced liver necroses].
    Beckert W
    Z Gesamte Inn Med; 1973 Jul; 28(14):413-7. PubMed ID: 4199479
    [No Abstract]   [Full Text] [Related]  

  • 19. [Re-evaluation of pyrazinamide].
    Kajiki A
    Kekkaku; 1994 Feb; 69(2):107-12. PubMed ID: 8126986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.